Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2068

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 2068
---
  
     6,731,823  
     282.1%
  
    Total operating expenses 
     16,198,036  
     7,675,049  
     8,522,987  
     111.0%
  
    Loss from operations 
     (16,198,036) 
     (7,675,049) 
     (8,522,987) 
     111.0%

    Other income (expense): 

    Gain from settlement of liabilities with vendor 
     3,339,223  
     8,144  
     3,331,079  
     40,902.2%
  
    Other expense 
     (672,378) 
     (62,182) 
     (610,196) 
     981.3%
  
    Change in fair value of derivative liabilities and earnout liabilities 
     5,200,117  
     301,170  
     4,898,946  
     1,626.6%
  
    Interest income, net 
     26,651  
     138,340  
     (111,689) 
     (80.7)%
  
    Total other income, net 
     7,893,613  
     385,472  
     7,508,140  
     1,947.78%

    Net loss 
     (8,304,423) 
     (7,289,577) 
     (1,014,846) 
     13.9%
  
    Deemed dividend 
     (2,784,839) 
     -  
     (2,784,839) 
     - 
  
    Net loss attributable to common stockholders 
    $(11,089,262) 
    $(7,289,577) 
    $(3,799,686) 
     52.1%

General and Administrative Expenses

General and administrative expenses were $9.1 million for the year
ended December 31, 2024, compared to $2.4 million for the year ended December 31, 2023, reflecting an increase of $6.7 million. The increase
in the year ended December 31, 2024, over the year ended December 31, 2023, was partially